INCY

Latest SEC Filings & News for INCY

2 most recent filings and news items mentioning INCY. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/INCY/news?limit=20"

Pull INCY filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
M&AJul 6, 2026Positive

Incyte Acquires Vega Therapeutics for $1.25B Upfront

Incyte completed the acquisition of Vega Therapeutics for $1.25 billion upfront, adding Phase 3 VWD asset VGA039. This deal significantly strengthens the company's hematology pipeline with a potential first-in-class therapy.

View filing at SEC.gov →
M&AJun 8, 2026Positive

Incyte to acquire Vega Therapeutics for $1.25B upfront plus $750M in milestones

Incyte agreed to acquire Vega Therapeutics, a Star Therapeutics subsidiary, to add VGA039, a Phase 3 bleeding disorder treatment candidate to its hematology portfolio. The deal expands Incyte's offerings in a core therapeutic area with potential commercial upside from a first-in-

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.